Insulet Corporation
PODDHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeInsulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. At a $11.36B market cap, Insulet Corporation ranks as a large-cap company within healthcare. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System.
Market Cap
$11.36B
Beta
1.11
P/E (TTM)
38.42
P/E (Fwd)
20.37
EPS (TTM)
$4.27
EPS (Fwd)
$8.05
ROE
23.0%
ROA
9.7%
Cash
$480.4M
Total Debt
$1.01B
Free CF
$253.4M
52W Change
-42.3%
Annual Financials
Cash vs Debt
The company holds $480.4M in cash, though total debt stands at $1.01B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $253.4M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 23.0% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 9.7% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $1.31B (2022) to $2.71B (2025), reflecting a 107% increase over the period.
Investors considering Insulet Corporation should weigh the typical risks associated with PODD's sector, size, and financial profile against their own risk tolerance and investment objectives. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing PODD.